TheranosticTrials.org

Clinical Trial · NCT04340765

18F-fluorocholine and 18F-fluoride PET in Prostate Cancer

Overview

Prostate cancer remains to be a public health problem around the world. For patients with prostate cancer, diphosphonate bone scintigraphy (BS) and pelvic tomographic imaging are major imaging tools to evaluate the disease spread. However, the conventional image modalities have only limited sensitivity and specificity. New imaging tracer with 18F-fluorocholine (18F-FCH) and old radiopharmaceuticals with NaF has showed promising results in detecting prostate cancers over bone scan. Nevertheless, the diagnostic performance of each tool has less been compared. The goal of this study is to compare the diagnostic performance of 18F-FCH PET/CT and NaF PET/CT for prostate cancer patients. The investigators prospectively enroll patients with the pathological diagnosis of prostate cancer and intended to receive radionuclide bone image. The patients will receive NaF PET/CT and 18F-FCH PET/CT. Each image will be evaluated by experienced interpreter for abnormal uptake suspicious for cancer spreading. The reference standard will be a combination of tissue correlation, imaging, laboratory and clinical data. Diagnostic performance of both PET/CT scans will be measured and calculated.

Sponsor

Buddhist Tzu Chi General Hospital

Phase

N/A

Contacts

Yu-Hung Chen, M.D. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04340765

Drug / Compound

fluorocholine

Isotope(s):
Target(s):
  • Phospholipid Metabolism
Ligand Class: Small Molecules

NaF

Isotope(s):
Target(s):
  • Bone Metabolism
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Patients are pathologically diagnosed with prostate adenocarcinoma.
  • Received NaF PET/CT.

Exclusion

  • The patients is classified as not suited for the exam by the investigators.
  • Diagnosed to have multiple cancers
  • Known allergic to investigational drug